These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30418124)

  • 1. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis.
    Castañeda S; Remuzgo-Martínez S; López-Mejías R; Genre F; Calvo-Alén J; Llorente I; Aurrecoechea E; Ortiz AM; Triguero A; Blanco R; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2019; 37(3):465-473. PubMed ID: 30418124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(1):83-6. PubMed ID: 16539824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis.
    Stavropoulos-Kalinoglou A; Metsios GS; Panoulas VF; Nightingale P; Koutedakis Y; Kitas GD
    Arthritis Res Ther; 2012 Jul; 14(4):R160. PubMed ID: 22765047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
    Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Insulin resistance and metabolic syndrome - a different image of disorders in rheumatoid arthritis and ankylosing spondylitis].
    Dąbrowski P; Majdan M
    Wiad Lek; 2015; 68(3):235-41. PubMed ID: 26753206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum interleukin 2 levels in patients with rheumatoid arthritis and correlation with insulin sensitivity.
    Oncül O; Top C; Ozkan S; Cavuşlu S; Danaci M
    J Int Med Res; 2002; 30(4):386-90. PubMed ID: 12235920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naïve to disease-modifying antirheumatic drugs.
    Yaşar Bilge NŞ; Kaşifoğlu N; Kaşifoğlu T; Şahin F; Gönüllü E; Korkmaz C
    Int J Rheum Dis; 2016 Jul; 19(7):665-71. PubMed ID: 26222244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.
    Lazzerini PE; Capecchi PL; Guidelli GM; Selvi E; Acampa M; Laghi-Pasini F
    Drug Des Devel Ther; 2016; 10():3083-3098. PubMed ID: 27713619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
    Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.
    Miranda-Filloy JA; Llorca J; Carnero-López B; González-Juanatey C; Blanco R; González-Gay MA
    Clin Exp Rheumatol; 2012; 30(6):850-5. PubMed ID: 22765845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis.
    Chen DY; Chen YM; Hsieh TY; Hsieh CW; Lin CC; Lan JL
    Arthritis Res Ther; 2015 Mar; 17(1):52. PubMed ID: 25889426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
    Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
    Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
    Snir A; Kessel A; Haj T; Rosner I; Slobodin G; Toubi E
    Clin Exp Rheumatol; 2011; 29(4):697-700. PubMed ID: 21813064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
    Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
    Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity is the main determinant of insulin resistance more than the circulating pro-inflammatory cytokines levels in rheumatoid arthritis patients.
    Castillo-Hernandez J; Maldonado-Cervantes MI; Reyes JP; Patiño-Marin N; Maldonado-Cervantes E; Solorzano-Rodriguez C; de la Cruz Mendoza E; Alvarado-Sanchez B
    Rev Bras Reumatol Engl Ed; 2017; 57(4):320-329. PubMed ID: 28743359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis.
    Pulito-Cueto V; Remuzgo-Martínez S; Genre F; Calvo-Alén J; Aurrecoechea E; Llorente I; Triguero-Martinez A; Blanco R; Llorca J; Ruiz-Lucea E; Rivera-García N; Gualillo O; López-Mejías R; Castañeda S; González-Gay MA
    Clin Exp Rheumatol; 2020; 38(6):1201-1205. PubMed ID: 32452351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study.
    Juhl P; Thudium CS; Gudmann NS; Karsdal MA; Bay-Jensen AC; Siebuhr AS
    Clin Exp Rheumatol; 2018; 36(4):568-574. PubMed ID: 29465346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Vazquez-Rodriguez TR; Garcia-Unzueta MT; Berja A; Miranda-Filloy JA; de Matias JM; Gonzalez-Juanatey C; Llorca J
    Clin Exp Rheumatol; 2010; 28(1):56-62. PubMed ID: 20346239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.